TABLE 1.
Study participants and demographic information
| Cohort | No. of subjects | No. of sites | Subject information |
|||||
|---|---|---|---|---|---|---|---|---|
| Gender (%) |
Age (median [range]) (yr) | Race (%) |
||||||
| Female | Male | Black | White | Other or unknown | ||||
| Effective immune response | ||||||||
| Spontaneously resolved | 27 | 2 | 96 | 4 | 25 (19–40) | 70 | 19 | 11 |
| Exposed | 27 | 3 | 19 | 81 | 31 (22–60) | 22 | 59 | 19 |
| Total | 54 | 4 | 52 | 48 | 30 (19–60) | 46 | 39 | 15 |
| Ineffective immune response | ||||||||
| PID | 24 | 5 | 100 | 0 | 27 (20–53) | 50 | 42 | 8 |
| Persistent infection | 13 | 1 | 100 | 0 | 23 (17–27) | 77 | 23 | 0 |
| Total | 37 | 5 | 100 | 0 | 25 (17–53) | 59 | 35 | 6 |
| Impact on pregnancy | ||||||||
| Successful pregnancy | 13 | 4 | 100 | 0 | 27 (19–37) | 62 | 23 | 15 |
| TFI | 16 | 3 | 100 | 0 | 24 (21–40) | 69 | 25 | 6 |
| Chlamydia naive | 21 | 2 | 76 | 24 | 19 (15–23) | 33 | 53 | 14 |